阶段(地层学)
医学
病态的
肺癌
临床终点
内科学
临床试验
肿瘤科
生物
古生物学
作者
Hyun Ae Jung,Daehwan Lee,Boram Park,Kiwon Lee,Ho Yun Lee,Tae Jung Kim,Yeong Jeong Jeon,Jung Hee Lee,Sung Yong Park,Jong Ho Cho,Yong‐Soo Choi,Sehhoon Park,Jong‐Mu Sun,Se‐Hoon Lee,Jin Seok Ahn,Myung‐Ju Ahn,Hong Kwan Kim
摘要
PURPOSE The surveillance protocol for early-stage non–small cell lung cancer (NSCLC) is not contingent upon individualized risk factors for recurrence. This study aimed to use comprehensive data from clinical practice to develop a deep-learning model for practical longitudinal monitoring. METHODS A multimodal deep-learning model with transformers was developed for real-time recurrence prediction using baseline clinical, pathological, and molecular data with longitudinal laboratory and radiologic data collected during surveillance. Patients with NSCLC (stage I to III) who underwent surgery with curative intent between January 2008 and September 2022 were included. The primary outcome was predicting recurrence within 1 year after the monitoring point. This study demonstrates the timely provision of risk scores (RADAR score) and determined thresholds and the corresponding AUC. RESULTS A total of 14,177 patients were enrolled (10,262 with stage I, 2,380 with stage II, and 1,703 with stage III). The model incorporated 64 clinical-pathological-molecular factors at baseline, along with longitudinal laboratory and computed tomography imaging interpretation data. The mean baseline RADAR score was 0.324 (standard deviation [SD], 0.256) in stage I, 0.660 (SD, 0.210) in stage II, and 0.824 (SD, 0.140) in stage III. The AUC for predicting relapse within 1 year of the monitoring point was 0.854 across all stages, with a sensitivity of 86.0% and a specificity of 71.3% (AUC = 0.872 in stage I, AUC = 0.737 in stage II, and AUC = 0.724 in stage III). CONCLUSION This pilot study introduces a deep-learning model that uses multimodal data from routine clinical practice to predict relapses in early-stage NSCLC. It demonstrates the timely provision of RADAR risk scores to clinicians for recurrence prediction, potentially guiding risk-adapted surveillance strategies and aggressive adjuvant systemic treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI